Retevmo


Aprueban primera terapia para el cáncer avanzado
Aprueban primera terapia para el cáncer avanzado

Retevmo es el nombre de la terapia que será utilizada para el cáncer metastásico como casos de cáncer de tiroides, sobre todo en adultos mayores que padecen esta anomalía.

Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers
Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers

Retevmo is a selective RET kinase inhibitor. Retevmo may affect both tumor cells and healthy cells, which can result in side effects. Retevmo is an oral prescription medicine, 120 mg or 160 mg based on weight, taken twice daily until disease progression or unacceptable toxicity